186 related articles for article (PubMed ID: 30073852)
1. Investigation of different types of nano drug delivery systems of atorvastatin for the treatment of hyperlipidemia.
Mathur M; Devi Vemula K
Drug Dev Ind Pharm; 2018 Dec; 44(12):2048-2060. PubMed ID: 30073852
[TBL] [Abstract][Full Text] [Related]
2. Combination of Phospholipid Complex and Submicron Emulsion Techniques for Improving Oral Bioavailability and Therapeutic Efficacy of Water-Insoluble Drug.
Qin L; Niu Y; Wang Y; Chen X
Mol Pharm; 2018 Mar; 15(3):1238-1247. PubMed ID: 29412674
[TBL] [Abstract][Full Text] [Related]
3. Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential.
Sharma M; Mehta I
Sci Rep; 2019 Nov; 9(1):16105. PubMed ID: 31695118
[TBL] [Abstract][Full Text] [Related]
4. Co-Delivery of Atorvastatin Nanocrystals in PLGA based in situ Gel for Anti-Hyperlipidemic Efficacy.
Kurakula M; Ahmed TA
Curr Drug Deliv; 2016; 13(2):211-20. PubMed ID: 26549039
[TBL] [Abstract][Full Text] [Related]
5. Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia.
Meena AK; Ratnam DV; Chandraiah G; Ankola DD; Rao PR; Kumar MN
Lipids; 2008 Mar; 43(3):231-41. PubMed ID: 18196308
[TBL] [Abstract][Full Text] [Related]
6. Modulating Drug Release and Enhancing the Oral Bioavailability of Torcetrapib with Solid Lipid Dispersion Formulations.
Liu Y; Salituro GM; Lee KJ; Bak A; Leung DH
AAPS PharmSciTech; 2015 Oct; 16(5):1091-100. PubMed ID: 25690735
[TBL] [Abstract][Full Text] [Related]
7. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles.
Suresh G; Manjunath K; Venkateswarlu V; Satyanarayana V
AAPS PharmSciTech; 2007 Mar; 8(1):24. PubMed ID: 17408223
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin calcium encapsulated eudragit nanoparticles with enhanced oral bioavailability, safety and efficacy profile.
Kumar N; Chaurasia S; Patel RR; Khan G; Kumar V; Mishra B
Pharm Dev Technol; 2017 Mar; 22(2):156-167. PubMed ID: 26555483
[TBL] [Abstract][Full Text] [Related]
9. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics.
Chen CC; Tsai TH; Huang ZR; Fang JY
Eur J Pharm Biopharm; 2010 Mar; 74(3):474-82. PubMed ID: 20060469
[TBL] [Abstract][Full Text] [Related]
10. Formulation and Evaluation of Atorvastatin Calcium-Poly-ε-Caprolactone Nanoparticles Loaded Ocular Inserts for Sustained Release and Antiinflammatory Efficacy.
Girgis GNS
Curr Pharm Biotechnol; 2020; 21(15):1688-1698. PubMed ID: 32427080
[TBL] [Abstract][Full Text] [Related]
11. PD-PK evaluation of freeze-dried atorvastatin calcium-loaded poly-ε-caprolactone nanoparticles.
Ahmed IS; El-Hosary R; Shalaby S; Abd-Rabo MM; Elkhateeb DG; Nour S
Int J Pharm; 2016 May; 504(1-2):70-9. PubMed ID: 27021467
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats.
Farrag SM; Hamzawy MA; El-Yamany MF; Saad MA; Nassar NN
Life Sci; 2018 Jun; 203():129-140. PubMed ID: 29694831
[TBL] [Abstract][Full Text] [Related]
13. A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics.
Singh A; Ahmad I; Ahmad S; Iqbal Z; Ahmad FJ
Drug Dev Ind Pharm; 2016 Sep; 42(9):1524-36. PubMed ID: 26902951
[TBL] [Abstract][Full Text] [Related]
14. Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers.
Rizwanullah M; Amin S; Ahmad J
J Drug Target; 2017 Jan; 25(1):58-74. PubMed ID: 27186665
[TBL] [Abstract][Full Text] [Related]
15. Preparation and characterisation of atorvastatin and curcumin-loaded chitosan nanoformulations for oral delivery in atherosclerosis.
J B VK; Ramakrishna S; Madhusudhan B
IET Nanobiotechnol; 2017 Feb; 11(1):96-103. PubMed ID: 28476969
[TBL] [Abstract][Full Text] [Related]
16. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
Khan S; Baboota S; Ali J; Narang RS; Narang JK
Drug Dev Ind Pharm; 2016; 42(2):209-20. PubMed ID: 26016780
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of lipid levels in triton induced hyperlipidemia rats through rosuvastatin calcium nanoparticles: Pharmacokinetic and pharmacodynamic studies.
Dudhipala NR; Ettireddy SR; Puchakayala GR
Chem Phys Lipids; 2021 Jul; 237():105081. PubMed ID: 33811848
[TBL] [Abstract][Full Text] [Related]
18. Systematic approach for the formulation and optimization of atorvastatin loaded solid lipid NANOAPARTICLES using response surface methodology.
Sarangi B; Jana U; Sahoo J; Mohanta GP; Manna PK
Biomed Microdevices; 2018 Jun; 20(3):53. PubMed ID: 29946758
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin-loaded solid lipid nanoparticles for enhanced anti-hyperlipidemic activity in hyperlipidemia animal model.
Rizvi SZH; Shah FA; Khan N; Muhammad I; Ali KH; Ansari MM; Din FU; Qureshi OS; Kim KW; Choe YH; Kim JK; Zeb A
Int J Pharm; 2019 Apr; 560():136-143. PubMed ID: 30753932
[TBL] [Abstract][Full Text] [Related]
20. Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects.
Joseph E; Reddi S; Rinwa V; Balwani G; Saha R
Eur J Pharm Sci; 2017 Jun; 104():315-325. PubMed ID: 28408348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
